Ameriprise Financial Inc. Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA)

Ameriprise Financial Inc. purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 14,926 shares of the company’s stock, valued at approximately $130,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alethea Capital Management LLC grew its holdings in Kura Oncology by 0.9% during the 4th quarter. Alethea Capital Management LLC now owns 558,442 shares of the company’s stock worth $4,864,000 after acquiring an additional 4,900 shares in the last quarter. Algert Global LLC grew its holdings in Kura Oncology by 224.6% during the 4th quarter. Algert Global LLC now owns 883,703 shares of the company’s stock worth $7,697,000 after acquiring an additional 611,427 shares in the last quarter. RA Capital Management L.P. acquired a new position in Kura Oncology during the 4th quarter worth approximately $38,769,000. Tudor Investment Corp ET AL acquired a new position in Kura Oncology during the 4th quarter worth approximately $338,000. Finally, Aquatic Capital Management LLC grew its holdings in Kura Oncology by 327.4% during the 4th quarter. Aquatic Capital Management LLC now owns 79,917 shares of the company’s stock worth $696,000 after acquiring an additional 61,217 shares in the last quarter.

Kura Oncology Trading Up 2.4%

Shares of KURA stock opened at $6.73 on Friday. The firm has a market cap of $582.65 million, a P/E ratio of -2.85 and a beta of 0.40. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm’s 50-day simple moving average is $6.07 and its 200-day simple moving average is $7.63.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts’ expectations of $39.08 million. As a group, equities analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

KURA has been the subject of several analyst reports. UBS Group lowered their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Barclays reduced their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research report on Friday, May 2nd. Wall Street Zen downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. JMP Securities restated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a research report on Wednesday. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.